Fig 1: CREG1 inhibits the degradation of LAMP2 in a FBXO27-dependent manner.a, b Western blotting analysis of LAMP2 or CREG1 protein expression in NMCMs following stimulation with CQ or MG132. c Real-time PCR analysis of the mRNA expression of Fbxo6 and Fbxo27 in CREG1-overexpressing NMCMs. d, e Western blotting analysis of the protein expression of FBXO6 and FBXO27 in CREG1-overexpressing NMCMs. f Real-time PCR analysis of the mRNA expression of Creg1 and Lamp2 in FBXO27-overexpressing NMCMs. g, h Western blotting analysis of the protein expression of CREG1 and LAMP2 in FBXO27-overexpressing NMCMs. i, j Effects of CREG1 and FBXO27 overexpression on the expression of autophagy-related proteins in NMCMs, as determined by western blotting. k Schematic illustration of the proposed mechanism of CREG1 in diabetic cardiomyopathy. NMCMs: neonatal mouse cardiomyocytes, CQ: chloroquine (20 μM, 24 h), PA: palmitate (400 μM, 24 h). **p < 0.01 vs. si-control or adcon or control; ##p < 0.01 vs. si-Creg1 or PA; &p < 0.05, &&p < 0.01 vs. si-Creg1 + CQ or FBXO27 + PA, n = 3.